Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Lun-Jie Yan ◽  
Sheng-Yu Yao ◽  
Guang-Xiao Meng ◽  
Kai-Xuan Liu ◽  
Hai-Chao Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Meta Analysis ◽  
Regional Disparities

scholarly journals Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis

2017 ◽  
Vol 15 (8) ◽  
pp. 1207-1217.e4 ◽  
Author(s):  
Aylin Tansel ◽  
Lior H. Katz ◽  
Hashem B. El-Serag ◽  
Aaron P. Thrift ◽  
Mayur Parepally ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Meta Analysis

562 - Mycophenolate Mofetil as Second-Line Therapy for Autoimmune Hepatitis: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 154 (6) ◽  
pp. S-1098
Author(s):  
Priscila Santiago ◽  
Leonardo Tamariz ◽  
Ingrid Schwartz ◽  
Cynthia Levy
Keyword(s):  
Systematic Review ◽  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Meta Analysis ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

The Efficacy of Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis: A Meta-Analysis and Systematic Review

2016 ◽  
Vol 111 ◽  
pp. S386
Author(s):  
Sheila D. Rustgi ◽  
Ioannis Konstantinidis ◽  
Rachel Pinotti ◽  
Thomas Schiano ◽  
Malcolm Wells
Keyword(s):  
Systematic Review ◽  
Mycophenolate Mofetil ◽  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Meta Analysis

scholarly journals Pregnancy for patients with autoimmune hepatitis: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Tengfei Si ◽  
Jonathon Graham ◽  
Dong Zhao ◽  
Zhenlin Huang ◽  
Yun Ma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Meta Analysis

miR-224 is an early-stage biomarker of hepatocellular carcinoma with miR-224 and miR-125b as prognostic biomarkers

2020 ◽  
Vol 14 (15) ◽  
pp. 1485-1500
Author(s):  
Lichao Yang ◽  
Chunmeng Wei ◽  
Yasi Li ◽  
Xiao He ◽  
Min He
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Survival Analysis ◽  
Sensitivity And Specificity ◽  
Poor Prognosis ◽  
Early Stage ◽  
Meta Analysis ◽  
Benign Lesion ◽  
Diagnostic Efficiency ◽  
Low Expression

Aim: The aim was to systematically investigate the miRNA biomarkers for early diagnosis of hepatocellular carcinoma (HCC). Materials & methods: A systematic review and meta-analysis of miRNA expression in HCC were performed. Results: A total of 4903 cases from 30 original studies were comprehensively analyzed. The sensitivity and specificity of miR-224 in discriminating early-stage HCC patients from benign lesion patients were 0.868 and 0.792, which were superior to α-fetoprotein. Combined miR-224 with α-fetoprotein, the sensitivity and specificity were increased to 0.882 and 0.808. Prognostic survival analysis showed low expression of miR-125b and high expression of miR-224 were associated with poor prognosis. Conclusion: miR-224 had a prominent diagnostic efficiency in early-stage HCC, with miR-224 and miR-125b being valuable in the prognostic diagnosis.

scholarly journals Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2984
Author(s):  
Stepan M. Esagian ◽  
Christos D. Kakos ◽  
Emmanouil Giorgakis ◽  
Lyle Burdine ◽  
J. Camilo Barreto ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Transarterial Chemoembolization ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Curative Intent ◽  
Randomized Controlled

The role of adjuvant transarterial chemoembolization (TACE) for patients with resectable hepatocellular carcinoma (HCC) undergoing hepatectomy is currently unclear. We performed a systematic review of the literature using the MEDLINE, Embase, and Cochrane Library databases. Random-effects meta-analysis was carried out to compare the overall survival (OS) and recurrence-free survival (RFS) of patients with resectable HCC undergoing hepatectomy followed by adjuvant TACE vs. hepatectomy alone in randomized controlled trials (RCTs). The risk of bias was assessed using the Risk of Bias 2.0 tool. Meta-regression analyses were performed to explore the effect of hepatitis B viral status, microvascular invasion, type of resection (anatomic vs. parenchymal-sparing), and tumor size on the outcomes. Ten eligible RCTs, reporting on 1216 patients in total, were identified. The combination of hepatectomy and adjuvant TACE was associated with superior OS (hazard ratio (HR): 0.66, 95% confidence interval (CI): 0.52 to 0.85; p < 0.001) and RFS (HR: 0.70, 95% CI: 0.56 to 0.88; p < 0.001) compared to hepatectomy alone. There were significant concerns regarding the risk of bias in most of the included studies. Overall, adjuvant TACE may be associated with an oncologic benefit in select HCC patients. However, the applicability of these findings may be limited to Eastern Asian populations, due to the geographically restricted sample. High-quality multinational RCTs, as well as predictive tools to optimize patient selection, are necessary before adjuvant TACE can be routinely implemented into standard practice. PROSPERO Registration ID: CRD42021245758.

Sign in / Sign up

Export Citation Format

Share Document